[New bone density conservation agents for osteoporosis under research and development: Anti-RANKL antibody].
Wada
Seiki
S
Department of Clinical Science, Faculty of Pharmaceutical Sciences, Josai International University.
Fukawa
Takeshi
T
Kamiya
Sadahiro
S
D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015519:Bone Density; D016723:Bone Remodeling; D001862:Bone Resorption; D001842:Bone and Bones / Q000378:metabolism; D002454:Cell Differentiation; D002986:Clinical Trials as Topic; D000069448:Denosumab; D015195:Drug Design; D006801:Humans; D010010:Osteoclasts / Q000166:cytology / Q000502:physiology; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D053245:RANK Ligand / Q000276:immunology* / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053245:RANK Ligand; D000069448:Denosumab